SUNDAY, JUNE 24, 2018

More than 3 million doses of BioThrax delivered to HHS

GAITHERSBURG, Md. — Emergent BioSolutions Inc. announced Dec. 14, 2006, that it has successfully completed the fourth-quarter 2006 deliveries of more than 3 million doses of BioThrax (Anthrax Vaccine Adsorbed) to the Department of Health and Human Services for placement into the nation’s Strategic National Stockpile.

The delivery of these doses, made under a May 2006 modified contract with HHS, represents fourth-quarter 2006 revenue of approximately $75 million.

Under the modified contract, the company is required to complete delivery of a total of 5 million doses of BioThrax to HHS prior to May 31, 2007, for a fixed price of $120 million. Since the contract modification, the company has delivered approximately 4 million doses of BioThrax and expects to deliver the balance during the first quarter of 2007.

Including the fourth-quarter 2006 deliveries, the company has supplied more than 9 million doses of BioThrax to HHS for inclusion in the stockpile.

“Over the past five years, we have consistently demonstrated our ability to meet our contractual obligations to deliver critically needed countermeasures to the U.S. government for placement into the Strategic National Stockpile,” said Robert G. Kramer, president and CEO of Emergent BioSolutions’ biodefense operations.

“Our success is directly attributable to our dedicated employees who exhibit a deep commitment to these principles every day in assuring the continued successful manufacture of the only FDA approved vaccine against anthrax.”

The company’s initial deliveries to HHS were pursuant to a May 2005 supply agreement under which the company agreed to supply an initial 5 million doses of BioThrax for placement into the SNS for a fixed price of $123 million. The company delivered the doses by February 2006, seven months ahead of schedule.

The SNS, which is administered by the U.S. Centers for Disease Control and Prevention, comprises large quantities of medicine and medical supplies to protect the American public if there is a public health emergency (terrorist attack, flu outbreak, earthquake) severe enough to cause local supplies to run out.

“We are proud to play a vital role in the strategic defense of the United States and the protection of its citizens from the threat of an anthrax attack,” said Fuad El-Hibri, chairman and CEO of Emergent BioSolutions.